# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Top performers in last week: RIVN (+21.37%), EMPH (+21.15%), DHI (+12.53%), BLD (+12.15%), BIDU (+11.80%), GLW (+11.54%), INSM ...
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $6...
Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $74 to $102.
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 to $95.
HC Wainwright & Co. analyst Andrew Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $70 t...